The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) is recommending that liver-specific contrast agents be used in liver MRI procedures.
In other recommendations included in its new consensus statement on liver MRI and clinical use of liver-specific contrast agents, ESGAR noted the hepatobiliary phase improves the detection and characterization of hepatocellular lesions and also that liver-specific contrast agents can improve the detection of hepatocellular carcinoma (HCC).
The consensus statement, which was published online on 21 July in European Radiology, is available for open access here.
